Jeffrey M Leiden sold $29M of VRTX
Executive Chairman at VERTEX PHARMACEUTICALS INC / MA. 63,781 shares at an average of $449.20, traded Dec 3, 2025, filed Dec 5, 2025.
Score components
- +20RoleChair
- +25Trade size$28.7M at market
- +20Share of holdings soldSold 73% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000875320-25-000242, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 3, 2025 | MOption exercise Common Stock10b5-1 | +63,781 | $86.52 | $5.5M | 87,807 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -4,469 | $440.40 | $2.0M | 83,338 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -1,320 | $441.26 | $582k | 82,018 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -2,469 | $443.21 | $1.1M | 79,549 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -4,352 | $444.36 | $1.9M | 75,197 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -7,899 | $445.56 | $3.5M | 67,298 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -1,152 | $447.05 | $515k | 66,146 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -2,320 | $448.78 | $1.0M | 63,826 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -5,880 | $449.84 | $2.6M | 57,946 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -5,809 | $451.20 | $2.6M | 52,137 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -15,681 | $452.20 | $7.1M | 36,456 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -10,360 | $453.34 | $4.7M | 26,096 | Dec 5, 2025 |
| Dec 3, 2025 | SOpen-market sale Common Stock10b5-1 | -2,070 | $455.22 | $942k | 24,026 | Dec 5, 2025 |
| Dec 4, 2025 | MOption exercise Common Stock10b5-1 | +1 | $91.05 | $91 | 24,027 | Dec 5, 2025 |
| Dec 3, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -63,781 | $0.00 | $0 | 0 | Dec 5, 2025 |
| Dec 4, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1 | $0.00 | $0 | 0 | Dec 5, 2025 |
Related signals
Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -7% | |
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -6% | |
| 35Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -6% | |
| 21Weak | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $173k 357 shares | -5% | |
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $108k 223 shares | -3% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $325k 668 shares | -3% | |
| 27Weak | VERTEX PHARMACEUTICALS INC / MA | Jonathan Biller EVP and Chief Legal Officer | $460k 945 shares | -6% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Mark E. Bunnage EVP, Chief Scientific Officer | $302k 620 shares | -8% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $1.1M 2,195 shares | -22% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $1.4M 2,848 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.